I have not yet seen any evidence that the trial is fully funded. Either way, they will need $5-$7M based on the clinical description. If they don't have it, it will need to come from dumping reserve shares into the market. So, at a share value of $.01, they would need to dump 500M - 700M shares- probably will go for a cool 1B shares.
I am hoping for the best, but I've been on this roller coaster for too long to unbuckle my seatbelt just yet.
Not filing on time (within the allowed extension period) is not an option. Everyone loses, if they were to be delisted/ suspended- most importantly the Mgt team and Auctus.